Institutional investors purchased a net $2.4 million shares of MLNT during the quarter ended September 2017. This may signal that the smart money is gaining interest in this company as the 25.89% of shares outstanding that institutional investors hold is actually below the Pharmaceuticals: Other industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
DEERFIELD MANAGEMENT COMPANY LP Bought 2.9 Million shares of Melinta Therapeutics, Inc...